COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
06/11/2025
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant [...]
Seer Reports Third Quarter 2025 Financial Results
06/11/2025
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
06/11/2025
CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
06/11/2025
MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
06/11/2025
Conference Call Scheduled for Friday, November 14, 2025 at 9:00 AM ET PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company [...]
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
06/11/2025
Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders Initiated Good Laboratory Practice (GLP) toxicology studies for CMP- [...]
Treace Medical Concepts Reports Third Quarter 2025 Financial Results
06/11/2025
PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Progyny, Inc. Announces Third Quarter 2025 Results
06/11/2025
Reports Revenue of $313.3 Million, Reflecting 9.3% Growth Raises Full Year Guidance to Reflect Continued Strength in Member Engagement Selling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% [...]
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
06/11/2025
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study [...]
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
06/11/2025
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, announces [...]
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
06/11/2025
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
06/11/2025
Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results [...]
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
06/11/2025
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
Teknova Reports Third Quarter 2025 Financial Results
06/11/2025
Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., [...]
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
06/11/2025
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL [...]
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
06/11/2025
Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed, supporting [...]
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
06/11/2025
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. [...]
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
06/11/2025
-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06 [...]
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
06/11/2025
Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced [...]

Pages